Royalty Report: Drugs, Therapeutic, cardiac – Collection: 995


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 8

Primary Industries

  • Drugs
  • Therapeutic
  • cardiac
  • Pharmaceuticals
  • Disease
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 995

License Grant
Under the terms of its strategic License Agreement with the Licensor holding ownership rights to certain clinical trial data of Gencaro, the Licensee will incur milestone and royalty obligations upon the occurrence of certain events.
License Property
GencaroTM (bucindolol hydrochloride) is a pharmacologically unique beta-blocker and mild vasodilator for chronic heart failure, or HF. Gencaro was the subject of a Phase 3 heart failure mortality trial involving more than 2,700 patients and was unique in gathering DNA data on over 1,000 of its participants.
Field of Use
The rights granted apply to the healthcare industry relating to heart failure.

IPSCIO Record ID: 27897

License Grant
Under the terms of its strategic License Agreement with the licensor, who holds ownership rights to certain clinical trial data of Gencaro, the licensee will incur milestone and royalty obligations upon the occurrence of certain events.
License Property
Gencaro is a beta-blocker and mild vasodilator indicated for the treatment of heart failure and other indications.

IPSCIO Record ID: 152350

License Grant
Licensor hereby assigns all of its rights under the Knoll Agreement to Licensee, and Licensee hereby assumes and agrees to perform, pay and discharge all of Licensees and Licensors obligations under the Knoll Agreement arising after the date of this Agreement, as such relate to the development or commercialization of Bucindolol or the Product in the Knoll Territory.
License Property
Product means Bucindolol and any finished product containing Bucindolol as the active ingredient.

Bucindolol means the compound Benzonitrile, 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-imethylethyl]amino]propoxy]-, monohydrochloride, also known under the trademark 'BEXTRA'.

Bucindolol Intellectual Property means the Trademarks and any patents, patent applications, copyrights, know-how, processes, formulae, data (including, but not limited to, preclinical, clinical, and marketing data) and trade secrets relating to the manufacture, development, commercialization or use of Bucindolol including any Improvement made or acquired by Licensor during the term of this Agreement.

BEAT means the Bucindolol Evaluation in Acute Myocardial Infarction Trial being conducted by Knoll.

BEST means the 'Beat-blocker Evaluation of Survival Trial' being conducted by the National Institutes of Health and the Veterans Administration, evaluating the use of Bucindolol in treating patients with congestive heart failure.

Trademark means the registered trademark BEXTRA(R), any other trademark, trade name or service mark used as a product identifier for Bucindolol and any variations thereof, in each case, whether or not registered.

Field of Use
'Field' means use of Bucindolol as a pharmaceutical therapy for congestive heart failure and/or left ventricular dysfunction.

IPSCIO Record ID: 178134

License Grant
Licensor grants the exclusive right in the Territory to bucindolol product improvements (e.g., sustained release formulation, improved or new indications, formulations and strengths), contingent upon Licensee reimbursing Licensor for costs relating to clinical trials and other tests conducted primarily for benefit of the Territory and 1/3 of all other development costs which have a worldwide benefit, including any previous product improvement development costs incurred by Licensor.
License Property
Bucindolol is a drug currently in Phase III clinical trials for congestive heart failure ('CHF' or 'heart failure').
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 27836

License Grant
Mydicar is a gene therapy currently being developed by the Licensee to treat advanced heart failure utilizing targeted proprietary AAV-1 technology. Presently, without a transplant the vast majority of heart failure patients die within 5-7 years. May 30th, 2010, Licensee presented at the European Society of Cardiology in Berlin 6-month data from CUPID, its’ Phase II trial of Mydicar. Based on our due diligence at the ESCO conference and our confidence that the CUPID trial met and exceeded its’ endpoints, we believe it is very likely that the Licensee will initiate a Phase III trial for Mydicar within the next 6-9 months.

IPSCIO Record ID: 26860

License Grant
The Company acquired exclusive rights from Licensor, an individual, to a United States patent issued in September 1989, covering a method of reducing mortality associated with chronic CHF in patients with impaired cardiac function by administering a combination of specified amounts of hydralazine and isosorbide dinitrate.
License Property
BIDIL® – an oral dosage formulation containing the combination of hydralazinehydrochloride and isosorbide dinitrate (two generically available vasodilators) – subject to FDA approval, as to which no assurance can be given, proposed to be used to improve symptoms and survival in patients with congestive heart failure (CHF) who are inappropriate for treatment with angiotensin – converting enzyme (ACE) inhibitors.
Field of Use
In March 1993, the Company submitted to the FDA an IND to commence human bioequivalency studies in the U.S.  Phase III clinical testing has been completed.

IPSCIO Record ID: 28684

License Grant
The Licensor is developing a cell therapy for the treatment of cardiovascular disease.

The Merger Agreement requires the Licensee to pay certain earn out payments following the first commercial sale of AMR-001 for the benefit of the former stockholders of the Licensor.

License Property
The Licensor's lead compound, AMR-001, now represents the Licensee's most clinically advanced therapeutic and has commenced enrollment for a Phase 2 trial to investigate AMR-001’s efficacy in preserving heart function after a heart attack.
Field of Use
The Licensee also expects to begin a Phase 1 clinical trial by 2013 to investigate AMR-001’s utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease.

IPSCIO Record ID: 25875

License Grant
The Canadian Licensor announced a collaboration with the Spanish Licensee to commercialize a technology for the treatment of chronic heart failure in certain countries of the European Union and Latin America.

Under the Agreement, the Licensee will have the exclusive rights to market the treatment of chronic heart failure and other cardiovascular conditions.  The technology has received European Union regulatory approval as a medical device under the CE Mark, which enables marketing of the product for the treatment of chronic heart failure in the 27 member countries of the European Union.  The Licensee has also acquired the right of first negotiation with respect to the remaining countries of the EU.  Under the Agreement, the commercial launch strategy in Europe will involve an initial commercialization phase during which the Licensee will target key opinion leaders in the major markets of Europe to ensure support for expanded use within the broader cardiology community.

License Property
Based on the current plan, the initial commercialization phase is expected to have a duration of approximately one year. The Licensor will be responsible for delivering the technology to the Licensee, which includes the single-use disposable cartridges required for the delivery of each monthly treatment.  

Celacade is a non-pharmacological treatment also known as Immune Modulation Therapy (IMT).  This therapy is using a modified sample of a patient's own blood to trick the immune system into fighting cardiac inflammation.  Celcade is a device-based outpatient procedure involving ex vivo exposure of 10ml autologous blood to heat, ultraviolet irradiation, controlled oxidative ozone therapy and subsequent intramuscular administration at monthly intervals.

Field of Use
The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.